AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2001, the company has made significant strides in developing innovative therapies for cancer treatment, focusing on targeted therapies and biomarker-driven approaches. With a strong presence in major operational regions, AVEO is dedicated to advancing its core products, including the FDA-approved drug FOTIVDA® (tivozanib), which is designed for the treatment of advanced renal cell carcinoma. This unique product stands out due to its selective inhibition of vascular endothelial growth factor (VEGF) receptors, offering a differentiated approach in oncology. AVEO's commitment to research and development has positioned it as a leader in the oncology sector, with notable achievements in clinical trials and partnerships that enhance its market presence. The company continues to strive for excellence in delivering effective cancer therapies to improve patient outcomes.
DitchCarbon Score
How does AVEO Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AVEO Pharmaceuticals, Inc.'s score of 62 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AVEO Pharmaceuticals, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of LG Chem, Ltd., which means that any climate commitments or emissions data may be inherited from its parent organisation. As of now, AVEO Pharmaceuticals has not established its own reduction targets or climate pledges. However, it is important to note that the climate initiatives and performance metrics may be influenced by LG Chem, Ltd., which has its own sustainability strategies and targets. Given the lack of specific emissions data and reduction initiatives from AVEO Pharmaceuticals, stakeholders may need to look to LG Chem, Ltd. for insights into the broader climate commitments and performance of the corporate family.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 5,317,349,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | 3,781,224,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 3 | 1,126,063,000 | - | 0,000,000,000 | 0,000,000,000 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AVEO Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
